Literature DB >> 166095

Inorganic pyrophosphate pool size and turnover rate in arthritic joints.

M Camerlain, D J McCarty, D C Silcox, A Jung.   

Abstract

Recent studies have shown elevated inorganic pyrophosphate (PPi) levels in most knee joint fluid supernates from patients with pseudogout (PG) or osteoarthritis (OA) and more modestly elevated levels in some supernates from patients with gout or rheumatoid arthritis (RA) relative to PPi levels found in the venous blood plasma of normal or arthritic subjects. We measured the intraarticular PPi pool and its rate of turnover to better understand the significance of the joint fluid-plasma PPi gradient. Preliminary studies in rabbits showed that (32-P)PPi passed from joint space to blood and vice versa without detectable hydrolysis. Incubation of natural or synthetic calcium pyrophosphate dihydrate (CPPD) microcrystals with synovial fluid in vitro in the presence of (32P)PPi tracer showed no change in PPi specific activity in the supernate over a 19-h period so that exchange of PPi in solution with that in CPPD microcrystals could be ignored. Clearance rates of (32P)PPi and of (33P)Pi, as determined by serially sampling the catheterized knee joints of volunteers with various types of arthritis over a 3-h period, were nearly identical. The (32P)PPi/(32P)Pi was determined in each sample. A mixture of a large excess of cold PPi did not influence the clearance rate of either nuclide. The quantity of PPi turned over per hous was calculated from the pool size as determined by isotope dilution and the turnover rate. The residual joint fluid nuclide was shown to be (32P)PPi. The PPi pool was generally smaller and the rate of turnover was greater in clinically inflamed joints. The mean plus or minus SEM pool size (mu-moles) and turnover rate (percent/hour) in PG knees was 0.23 plus or minus 0.07 and 117 plus or minus 11.9, hydrolysis rate (%/h) to Pi was 27.7 plus or minus 13.2; in OA knees: 0.45 plus or minus 0.26 and 72 plus or minus 9.2, hydrolysis 6.9 plus or minus 0.9; in gouty knees: 0.8 plus or minus 0.41 and 50 plus or minus 11.6, hydrolysis 9.8 plus or minus 2.8; and in RA knees: 0.14 plus or minus 0.14 and 114 plus or minus 35.8, hydrolysis 236 plus or minus 116. PPi turnover (mumoles/hour) correlated with the degree of OA change present in the joint as graded by radiologic criteria irrespective of the clinical diagnosis. Mean PPi turnover in joints with advanced OA was greater than in those with mild or moderate changes (P smaller than 0.001), but the mild and moderate groups showed no significant difference. We conclude that synovial PPi turnover and elevated PPi fluid concentrations are not specific for PG patients, and that these factors alone cannot be the only determinants of CPPD crystal deposition.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 166095      PMCID: PMC301892          DOI: 10.1172/JCI108056

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  PREVALENCE OF CALCIFIED MENISCAL CARTILAGE IN ELDERLY PERSONS.

Authors:  J BOCHER; H J MANKIN; R N BERK; G P RODNAN
Journal:  N Engl J Med       Date:  1965-05-27       Impact factor: 91.245

2.  CHONDROCALCINOSIS COINCIDENTAL TO OTHER RHEUMATIC DISEASE.

Authors:  R W MOSKOWITZ; D KATZ
Journal:  Arch Intern Med       Date:  1965-06

3.  An improved method for the micro-determination of inorganic phosphate in small volumes of biological fluids.

Authors:  R J HALL
Journal:  J Med Lab Technol       Date:  1963-04

4.  Crystal-induced inflammation; syndromes of gout and pseudogout.

Authors:  D J MCCARTY
Journal:  Geriatrics       Date:  1963-06

5.  Some formal approaches to the analysis of kinetic data in terms of linear compartmental systems.

Authors:  M BERMAN; M F WEISS; E SHAHN
Journal:  Biophys J       Date:  1962-05       Impact factor: 4.033

6.  The routine fitting of kinetic data to models: a mathematical formalism for digital computers.

Authors:  M BERMAN; E SHAHN; M F WEISS
Journal:  Biophys J       Date:  1962-05       Impact factor: 4.033

7.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

8.  Identification of urate crystals in gouty synovial fluid.

Authors:  D J MCCARTY; J L HOLLANDER
Journal:  Ann Intern Med       Date:  1961-03       Impact factor: 25.391

9.  Radiological assessment of osteo-arthrosis.

Authors:  J H KELLGREN; J S LAWRENCE
Journal:  Ann Rheum Dis       Date:  1957-12       Impact factor: 19.103

10.  Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout).

Authors:  R G Russell; S Bisaz; H Fleisch; H L Currey; H M Rubinstein; A A Dietz; I Boussina; A Micheli; G Fallet
Journal:  Lancet       Date:  1970-10-31       Impact factor: 79.321

View more
  10 in total

1.  Crystals and arthritis.

Authors: 
Journal:  Br Med J       Date:  1979-03-10

2.  Interaction of polymorphonuclear leukocytes with calcium pyrophosphate dihydrate crystals deposited in chondrocalcinosis cartilage.

Authors:  H Ishikawa; Y Ueba; T Isobe; K Hirohata
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

3.  Factors affecting the solubility of calcium pyrophosphate dihydrate crystals.

Authors:  R M Bennett; J R Lehr; D J McCarty
Journal:  J Clin Invest       Date:  1975-12       Impact factor: 14.808

4.  Understanding inorganic pyrophosphate metabolism: toward prevention of calcium pyrophosphate dihydrate crystal deposition.

Authors:  L M Ryan; D J McCarty
Journal:  Ann Rheum Dis       Date:  1995-12       Impact factor: 19.103

5.  Proceedings of a symposium on crystal-related arthropathies. 22 October and 23 October, 1982, Bristol Polytechnic, Bristol.

Authors: 
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

Review 6.  Crystals, joints, and consternation.

Authors:  D McCarty
Journal:  Ann Rheum Dis       Date:  1983-06       Impact factor: 19.103

Review 7.  Pathogenesis of chondrocalcinosis and pseudogout. Metabolism of inorganic pyrophosphate and production of calcium pyrophosphate dihydrate crystals.

Authors:  A Caswell; D F Guilland-Cumming; P R Hearn; M K McGuire; R G Russell
Journal:  Ann Rheum Dis       Date:  1983-08       Impact factor: 19.103

8.  Pyrophosphohydrolase activity and inorganic pyrophosphate content of cultured human skin fibroblasts. Elevated levels in some patients with calcium pyrophosphate dihydrate deposition disease.

Authors:  L M Ryan; R L Wortmann; B Karas; M P Lynch; D J McCarty
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

9.  Formation of calcium pyrophosphate crystals in vitro: implications for calcium pyrophosphate crystal deposition disease (pseudogout).

Authors:  P R Hearn; R G Russell
Journal:  Ann Rheum Dis       Date:  1980-06       Impact factor: 19.103

10.  Role of phosphate, pyrophosphate, adenine nucleotides and sulfate in activating production of the superoxide radical by macrophages, and in formation of rat paw edema.

Authors:  Y Oyanagui
Journal:  Agents Actions       Date:  1977-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.